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Sirtuin 2 (SIRT2) is one of the seven members of the family of NAD+-dependent histone 
deacetylases. Sirtuins target histones and non-histone proteins according to their sub-
cellular localization, influencing various biological processes. SIRT2 resides mainly in the 
cytoplasm and regulates cytoskeleton dynamics, cell cycle, and metabolic pathways. As 
such, SIRT2 has been implicated in the pathogenesis of neurodegenerative, metabolic, 
oncologic, and chronic inflammatory disorders. This motivated the development of 
SIRT2-directed therapies for clinical purposes. However, the impact of SIRT2 on anti-
microbial host defense is largely unknown. Here, we address this question using SIRT2 
knockout mice. We show that SIRT2 is the most highly expressed sirtuin in myeloid cells, 
especially macrophages. SIRT2 deficiency does not affect immune cell development 
and marginally impacts on intracellular signaling and cytokine production by splenocytes 
and macrophages. However, SIRT2 deficiency enhances bacterial phagocytosis by 
macrophages. In line with these observations, in preclinical models, SIRT2 deficiency 
increases survival of mice with chronic staphylococcal infection, while having no effect 
on the course of toxic shock syndrome toxin-1, LPS or TNF-induced shock, fulminant 
Escherichia coli peritonitis, sub-lethal Klebsiella pneumoniae pneumonia, and chronic 
candidiasis. Altogether, these data support the safety profile of SIRT2 inhibitors under 
clinical development in terms of susceptibility to infections.
Keywords: sirtuin, innate immunity, cytokine, macrophage, phagocytosis, sepsis, histone deacetylase, metabolism
inTrODUcTiOn
Innate immune cells are at the vanguard of host defense against microbial infections. Monocytes/
macrophages and dendritic cells (DCs) sense microbial or danger-associated molecular patterns 
(MAMPs and DAMPs released by injured or stressed cells) through pattern recognition receptors 
(PRRs) such as toll-like receptors (TLRs), NOD-like receptors, C-type lectins, scavenger receptors, 
RIG-I-like receptors, and intra-cytosolic DNA sensors (1, 2). The interaction of MAMPs or DAMPs 
with PRRs triggers the mitogen-activated protein kinases (MAPKs), nuclear factor-κB (NF-κB), and 
interferon (IFN) response factor signaling pathways that coordinate immune gene expression. The 
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cellular and soluble mediators mobilized upon infection tightly 
regulate the development of the inflammatory response, the 
establishment of antimicrobial cellular and humoral responses, 
and the restoration of homeostasis once pathogens have been 
contained or eradicated.
The superfamily of histone deacetylases (HDACs) comprises 
eleven Zn-dependent HDACs (HDAC1-11) and seven NAD+-
dependent sirtuins (SIRT1-7). HDACs are epigenetic erasers 
catalyzing histone deacetylation, chromatin compaction, and 
transcriptional repression. In addition, HDACs target thousands 
of non-histone proteins affecting many biological processes (3). 
The subfamily of sirtuins attracted much interest when sirtuins 
were proposed to promote longevity and represent attractive 
therapeutic targets for age-related pathologies, such as type 
2 diabetes, as well as neurodegenerative, cardiovascular, and 
oncologic diseases (4–6). Our knowledge about the impact of 
sirtuins on innate immune responses is limited. Most studies 
have focused on SIRT1 and SIRT6, resulting in an overall complex 
picture attributing both proinflammatory and anti-inflammatory 
properties to sirtuins (7).
Sirtuin 2 (SIRT2) was originally reported to colocalize with the 
microtubule network and to deacetylate α-tubulin (8). Indeed, 
SIRT2 is mainly cytoplasmic, although it can translocate during 
the G2/M transition phase of cell cycle into the nucleus where it 
deacetylates histone H4 lysine 16 (9). Of note, SIRT2 possesses a 
proficient demyristoylation activity, the physiological relevance 
of which remains to be established (10). By targeting numerous 
proteins besides histones, SIRT2 regulates cytoskeleton dynam-
ics, cell cycle, and metabolic pathways including inhibition of 
adipogenesis and promotion of lipolysis and gluconeogenesis. 
Additionally, SIRT2 can act as a tumor suppressor gene, and is 
involved in myelogenesis and other brain functions. Accordingly, 
SIRT2 has been implicated in tumorigenesis and neurodegenera-
tion, and likely plays a role in metabolic disorders, such as obesity 
and type 2 diabetes (11–13).
With respect to inflammatory processes, SIRT2 was first 
shown to deacetylate NF-κB p65, resulting in the expression of 
a subset of p65-dependent genes in mouse embryonic fibroblasts 
(14). SIRT2 deficiency sustained brain inflammation in a model 
of traumatic brain injury and increased the severity of collagen-
induced arthritis and colitis (15–17). However, SIRT2 deficiency 
was also reported to decrease NF-κB p65-mediated inflammatory 
response, renal tubular inflammation, and ischemia reperfusion-
induced hepatocellular inflammation (18–20). Finally, in an 
experimental stroke model, SIRT2 deficiency preserved neu-
rological functions without affecting inflammatory parameters 
(21). Overall, the function of SIRT2 in sterile and chronic inflam-
matory disorders appears to be context dependent.
Because sirtuins are pleiotropic and in consideration of the 
development of sirtuin-targeting drugs for clinical conditions, 
we sought to delineate the role of SIRT2 in the innate immune 
response. To this end, we used SIRT2 knockout mice to inves-
tigate the response of immune cells to immunological and 
microbial stimuli using in vitro experiments and in vivo preclini-
cal models. Preclinical models included models of shock as well 
as Gram-negative and Gram-positive bacterial infections and 
fungal infection. Overall, SIRT2 deficiency does not modulate 
cytokine production by innate immune cells, but enhances bac-
terial phagocytosis by macrophages. SIRT2 deficiency protects 
from chronic staphylococcal infection, while having no impact 
on toxic shock, endotoxemia, fulminant peritonitis, non-lethal 
pneumonia, and chronic candidiasis. These data largely support 
the safety, in terms of susceptibility to infections, of SIRT2 inhibi-
tors developed for clinical applications.
MaTerials anD MeThODs
Mice, cells, and reagents
8- to 12-week-old female BALB/cByJ mice, C57BL/6J mice 
(Charles River Laboratories, Saint-Germain-sur-l’Arbresle, 
France), and SIRT2 knockout mice backcrossed 12 times on a 
C57BL/6J background (15) were used. Mice were housed under 
specific pathogen-free conditions and free of mouse norovirus. 
Splenocytes were cultured in RPMI 1640 medium containing 2 mM 
glutamine, 50 µM 2-ME, 100 IU/ml penicillin, 100 µg/ml strep-
tomycin (Invitrogen, San Diego, CA) and 10% heat-inactivated 
fetal calf serum (FCS; Sigma-Aldrich, St. Louis, MO) (22). Bone 
marrow (BM) cells were cultured in IMDM (Invitrogen) contain-
ing 50 µM 2-ME, penicillin, streptomycin, and 10% FCS. Medium 
was supplemented with 20 ng/ml M-CSF, 20 ng/ml GM-CSF plus 
20 ng/ml IL-4 (ProSpec, East Brunswick, NJ) or 200 ng/ml FMS-
like tyrosine kinase 3 ligand (Flt3L, Shenandoah biotechnology, 
Warwick, PA) to generate BM-derived macrophages (BMDMs), 
BM-derived dendritic cells (BMDCs), or Flt3L-DCs, respectively. 
BMDCs were collected after 6 days. BMDMs and Flt3L-DCs were 
collected after 7 days of culture. Cells (1, 5, and 20 × 105) were 
seeded in 96-well, 24-well or 6-well plates in complete medium 
without growth factors and antibiotics unless specified.
Salmonella minnesota ultra pure lipopolysaccharide (LPS) was 
from List Biologicals Laboratories (Campbell, CA), Pam3CSK4 
from EMC microcollections (Tübingen, Germany), CpG ODN 
1826 (CpG) from InvivoGen (San Diego, CA, USA), toxic shock 
syndrome toxin-1 (TSST-1) and staphylococcal enterotoxin B 
(SEB) from Toxin Technology (Sarasota, FL, USA), concanavalin 
A and phytohemagglutinin (PHA) from Sigma-Aldrich, and 
anti-CD3ε and anti-CD28 antibodies (clones 145-2C11 and 
37.51) from eBioscience (San Diego, CA, USA). Clinical strains 
of Escherichia coli (E. coli) O18, E. coli J5, E. coli O111, Salmonella 
enterica serovar Typhimurium C5 (Salmonella Typhimurium), 
Klebsiella pneumoniae caroli (K. pneumoniae), Neisseria men-
ingitis, Streptococcus pneumoniae, Staphylococcus aureus AW7 
(S. aureus), and Group B Streptococcus (GBS) were grown in 
brain heart infusion broth (BD Biosciences, Erembodegem, 
Belgium) (23–27). Candida albicans 5102 (C. albicans) (22) was 
cultured in yeast extract–peptone–dextrose (BD Biosciences). 
Microorganisms were washed in PBS and adjusted at 1010 CFU/ml. 
For in vitro stimulation, bacteria were heat-inactivated for 2 h at 
56°C. Nocodazole and 2-deoxyglucose were from Sigma-Aldrich, 
cytochalasin D from Millipore (Billerica, MA, USA).
rna analyses
Total RNA was isolated, reverse transcribed (RNeasy and 
QuantiTect reverse transcription kits, Qiagen, Hilden, Germany), 
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and used in real-time PCRs conducted with a QuantStudio™ 12K 
Flex system (Life Technologies, Carlsbad, CA, USA). Reactions 
consisted of 1.25 µl cDNA, 1.25 µl H2O, 0.62 µl 10 nM primers 
[Table S1 in Supplementary Material and Ref. (28, 29)], and 
3.12 µl Fast SYBR® Green Master Mix (Life Technologies) and 
were tested in triplicate. Gene specific expression was normalized 
to hypoxanthine guanine phosphoribosyl transferase expression. 
Sirt2 expression levels in organs were extracted from the BioGPS 
resource (http://biogps.org).
Western Blot analyses
Nuclear and total protein extracts were submitted to PAGE and 
transferred onto nitrocellulose membranes (30, 31). Membranes 
were incubated with antibodies directed against SIRT2, acetylated 
α-tubulin, total α-tubulin, total and phosphorylated ERK1/2, 
p38, JNK, and NF-κB p65 and TATA-box binding protein (used 
as a control of nuclear extracts) (see antibody description in Table 
S2 in Supplementary Material), then with a secondary horserad-
ish peroxidase-conjugated antibody (Sigma-Aldrich) (32). Blots 
were imaged with the enhanced chemiluminescence Western 
blotting system (GE Healthcare, Little Chalfont, Royaume-Uni). 
Images were recorded using a Fusion Fx system (Viber Lourmat, 
Collégien, France).
Flow cytometry
Single cell suspensions from thymus and spleen, or BMDMs were 
enumerated and incubated with 2.4G2 monoclonal antibody 
(mAb). Immune cell subpopulations were tracked by staining 
performed using mAbs described in Table S2 in Supplementary 
Material. Splenic CD4+ CD25+ Foxp3+ cells were detected using 
The Mouse Regulatory T Cell Staining Kit (eBioscience). Data 
were acquired using a LSR II flow cytometer (BD Biosciences) 
and analyzed using FlowJo Version 10.2 software (FlowJo LLC, 
Ashland, OR, USA) (33).
Proliferation assay
The proliferation of 1.5  ×  105 splenocytes cultured for 48  h in 
96-well plates was quantified by measuring 3H-thymidine incor-
poration over 18 h (34).
cytokine Measurements
Cytokine concentrations were quantified using DuoSet ELISA kits 
(R&D Systems, Abingdon, UK) or Luminex assays (Affimetrix 
eBioscience, Vienna, Austria) (35).
In Vivo Models
8- to 12-week-old female SIRT2+/+ and SIRT2−/− mice (6–13 mice 
per group) matched for age were used. To analyze the response 
to TSST-1, mice were challenged intraperitoneally (i.p.) with 
TSST-1 (0.5 mg/kg). Models of endotoxic shock were performed 
by challenging mice i.p. with LPS (10 and 25 mg/kg). To induce 
TNF shock, mice were sensitized with d-galactosamine (30 mg/
kg i.p., Sigma-Aldrich) just before being challenged with TNF 
(25  mg/kg i.p., Preprotech, Rocky Hill, NJ, USA). Bacterial 
sepsis was induced by challenging mice i.p. with 105 CFU E. coli 
O18, intravenously (i.v.) with 107 CFU S. aureus or 105 CFU C. 
albicans or intranasally (i.n.) with 30 CFU K. pneumoniae. Blood 
and spleen were collected 0, 1, 6, 8, 24, or 48 h post-challenge to 
quantify cytokines and bacteria (28). Body weight loss, severity 
score, and survival were registered at least once daily. The severity 
score was graded from 1 to 5 (36). Animals were euthanized when 
they met a severity score of 4. Two to three operators performed 
animal follow-up.
Phagocytosis assays
Fluoresbrite® Yellow Green Microspheres (Polysciences Inc, 
Warrington, PA, USA) or FITC-labeled bacteria were added to 
cells at a ratio of 10 beads or bacteria/cell. After 1 h, cells were 
washed, incubated for 1  min with trypan blue (0.25  mg/ml) 
and analyzed by flow cytometry. When specified, beads were 
opsonized with serum for 30  min at 37°C. To assess phagocy-
tosis of live bacteria, BMDMs (in quadruplicates or sextuplates) 
were incubated for 1 h with E. coli O18, S. aureus, and GBS (10 
bacteria/cell). Non-adherent and extracellular bacteria were 
removed by washing and killed by a 30-min exposure to 100 µg/
ml gentamicin (Essex Chemie, Luzern, Switzerland; for E. coli 
and GBS) or 10 µg/ml ciprofloxacin (Fresenius Kabi, Oberdorf, 
Switzerland; for S. aureus). Serial dilutions of cell lysates were 
plated on agar plates. Colonies were enumerated to calculate the 
number of phagocytosed bacteria.
glycolytic activity
The glycolytic activity of BMDMs was analyzed using a 96-well 
format Seahorse XFe® system and the Seahorse XF Glycolysis 
Stress Test Kit (Agilent Technologies, Santa Clara, CA, USA). 
Briefly, 4 × 104 BMDMs were plated in 96-well plates in IMDM 
medium. The next day, cells were incubated with or without 
5 × 107 CFU/ml heat-killed S. aureus and rested 1 h in Seahorse 
medium without glucose. The glycolytic capacity was assessed 
by measuring the extracellular acidification rate following the 
sequentially addition of 10 mM glucose, 1 µM oligomycin, and 
50  mM 2-deoxy-glucose (2-DG) according to manufacturer’s 
instructions.
statistical analyses
Comparisons between the different groups were performed by 
analysis of variance followed by two-tailed unpaired Student’s 
t-test. The Kaplan–Meier method was used for building survival 
curves and differences were analyzed by the log-rank sum test. 
All analyses were performed using PRISM (GraphPad Software). 
P values were two-sided, and P < 0.05 was considered to indicate 
statistical significance.
resUlTs
sirT2 is highly expressed  
by Myeloid cells
SIRT1-7 mRNA expression was quantified in BM, BMDMs, and 
DCs (conventional BMDCs and Flt3L-derived DCs) (Figure 1A). 
SIRT2 was the most highly expressed sirtuin in all populations. 
SIRT2 was also the predominantly expressed sirtuin in RAW 264.7 
FigUre 1 | Sirt2 is strongly expressed in myeloid cells. (a,B) Sirt1-7 mRNA levels in bone marrow (BM), BM-derived macrophages (BMDMs) and dendritic cells 
(BMDCs), and Flt3L-derived DCs (a) and RAW 264.7 macrophages (B) analyzed by RT-PCR and normalized to Hprt mRNA levels. Data are means ± SD of triplicate 
samples from one experiment performed with four BALB/c mice (a) or three preparations of RAW 264.7 macrophages (B). (c) Sirt2 mRNA expression levels in a 
panel of cells (extracted from http://biogps.org). (D,e) Sirt2 mRNA (D) and Sirtuin 2 (SIRT2) protein (e) expression in SIRT2+/+ and SIRT2−/− BMDMs assessed by 
RT-PCR and western blotting, respectively. Data are means ± SD from one experiment performed with three mice (D). (F) Sirt1-7 mRNA expression levels in 
SIRT2−/− BMDMs, expressed relative to the mRNA levels in SIRT2+/+ BMDMs set at 100%. Data are means ± SD from one experiment performed with three mice. 
A.U., arbitrary units. Full-length blots of panel (e) are presented in Figure S1 in Supplementary Material.
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macrophages and in the spleen, liver, and kidneys (Figure 1B and 
data not shown). Western blot analyses confirmed SIRT2 protein 
expression in BMDMs (see below). Primary osteoblasts, osteo-
clasts, macrophages, and mast cells expressed 2.6-fold to 7.1-fold 
higher levels of SIRT2 mRNA than granulocytes, NK cells, T cells, 
B cells, DCs, and thymocytes (Figure 1C). Overall, SIRT2 was 
highly expressed by myeloid-derived cells, suggesting that it 
could play a role in the control of immune responses. To address 
this question, SIRT2-deficient mice were used [Figures 1D,E and 
Ref. (15)].
TaBle 2 | Splenic cell subsets in SIRT2+/+ and SIRT2−/− mice.
cell subset sirT2+/+ sirT2−/−
CD3+ T cells (%) 27.3 ± 4.6 36.3 ± 4.8
 CD4+ 62.3 ± 2.7 61.5 ± 4.3
 CD4+ CD44low CD62Lhigh (naive) 46.0 ± 2.9 43.7 ± 6.8
 CD4+ CD44high CD62Llow (memory) 16.3 ± 2.9 17.8 ± 6.9
 CD8+ 31.5 ± 2.0 32.0 ± 2.9
 CD8+ CD44low CD62Lhigh (naive) 23.1 ± 0.5 23.5 ± 0.3
 CD8+ CD44high CD62Llow (memory) 8.4 ± 0.5 8.5 ± 0.3
 CD4− CD8− 1.3 ± 0.2 1.6 ± 0.2
B220+ B cells (%) 52.2 ± 7.4 51.3 ± 3.1
 B220+ IgD+ CD23+ (mature) 45.6 ± 1.2 44.1 ± 0.9
 B220+, non-IgD+/CD23+ (immature) 6.6 ± 1.2 7.2 ± 0.9
CD11c+ dendritic cells (%) 6.6 ± 0.2 6.4 ± 0.6
 B220− 62.8 ± 2.5 62.8 ± 4.7
 B220+ 37.2 ± 2.5 37.2 ± 4.7
CD4+ CD25+ Foxp3+ Tregs (%) 4.5 ± 0.4 4.7 ± 0.2
Data are means ± SD of four animals per group expressed as the percentage of 
CD3+, B220+, CD11c+, and CD4+ Foxp3+ splenic cells or the percentage of the CD3+, 
B220+, and CD11c+ parental populations expressing CD4, CD8, CD44, CD62L, IgD, 
and CD23. Total cell numbers were 74.2 ± 5.6 and 67.4 ± 8.7 millions per spleen 
in SIRT2+/+ and SIRT2−/− mice, respectively. No statistically significant differences in 
subset percentages or absolute numbers were detected.
TaBle 1 | Thymic cell subsets in SIRT2+/+ and SIRT2−/− mice.
cell subset sirT2+/+ sirT2−/−
CD4+ CD8+ 82.3 ± 3.1 82.9 ± 0.4
CD4− CD8− 2.0 ± 0.6 1.8 ± 0.2
 CD25+ CD44+ 1.8 ± 0.6 1.6 ± 0.5
 CD25− CD44+ 0.2 ± 0.01 0.2 ± 0.01
 CD25+ CD44− 1.4 ± 0.6 1.3 ± 0.4
 CD25− CD44− 96.6 ± 1.2 96.9 ± 1.0
CD4+ CD8− 12.0 ± 2.3 12.1 ± 0.7
CD4− CD8+ 3.6 ± 0.3 3.3 ± 0.8
Data are means ± SD of four animals per group expressed as the percentage of total 
cells (CD4+ CD8+, CD4− CD8−, CD4+ CD8−, and CD4− CD8+) or percentage of CD4− 
CD8− parental cells (CD25+ CD44+, CD25− CD44+, CD25+ CD44− and CD25− CD44−). 
Total cell numbers were 49.2 ± 15.4 and 55.2 ± 5.7 millions per thymus in SIRT2+/+ 
and SIRT2−/− mice, respectively. No statistically significant differences in subset 
percentages or absolute numbers were detected.
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sirT2 Deficiency has no Major impact  
on the Development of immune cells  
and host response to TssT-1
SIRT2−/− mice were described previously (15). These mice were 
born at the expected Mendelian ratio and developed without 
abnormalities. SIRT2 mRNA and protein were undetectable in 
SIRT2−/− BMDMs (Figures 1D,E). Expression levels of Sirt1 and 
Sirt3-7 mRNA were unaltered in SIRT2−/− BMDMs (Figure 1F), 
suggesting that the lack of SIRT2 was not compensated by an 
increase in expression of other sirtuins.
Compared to SIRT2+/+ mice, SIRT2−/− mice expressed normal 
proportions and absolute numbers of CD4/CD8 double negative 
(DN1–4), double positive, and single positive (SP) thymocytes 
(Table 1). Additionally, SIRT2−/− mice had normal populations 
of splenic T cells (DN, SP, naïve, and memory), B cells (immature 
and mature B cells), DCs (B220− CD11c+ cDCs and B220+ CD11c+ 
pDCs), and Foxp3+ regulatory T cells (Table 2). Therefore, SIRT2 
had no major impact on immune cell development.
As a first approach to evaluate whether SIRT2 influenced 
immune responses, SIRT2+/+ and SIRT2−/− splenocytes were 
exposed to microbial and immunological stimuli: LPS, CpG, 
concanavalin A, anti-CD3/CD28, PHA, TSST-1, and SEB. The 
proliferation and production of IL-2 and IFNγ (measured by 
ELISA) by splenocytes were not affected by SIRT2 deficiency 
(Figures  2A,B). In agreement, blood concentrations of IFNγ 
were similar in SIRT2+/+ and SIRT2−/− mice injected with TSST-1 
(Figure 2C), a staphylococcal superantigen responsible of toxic 
shock syndrome. A Luminex assay was then used to quantify TNF, 
IL-6, IL-10, IL-12p70, CCL3/Mip1α, CCL4/Mip1β, and CCL5/
Rantes secretion by splenocytes exposed to LPS, CpG, conca-
navalin A, anti-CD3/CD28, PHA, TSST-1, and SEB (Figure 2D). 
No differences were observed between SIRT2+/+ and SIRT2−/− 
splenocytes apart from a 20–28% reduction of LPS-induced IL-6, 
IL-10, and CCL5 and anti-CD3/CD28-induced CCL4, while the 
secretion of CCL5 was increased in response to anti-CD3/CD28.
sirT2 Deficiency increases  
Phagocytosis by Macrophages
Macrophages are professional phagocytic cells that play a major 
role in antimicrobial host defenses. Therefore, we tested whether 
SIRT2 deficiency had an effect on phagocytosis by BMDMs. 
SIRT2+/+ and SIRT2−/− BMDMs were incubated with fluorescent 
beads and analyzed by flow cytometry (Figures 3A–C). A higher 
percentage of SIRT2−/− than SIRT2+/+ BMDMs phagocytosed 
beads (32.4 ± 1.9 vs 24.5 ± 1.2 percent positive cells, P = 0.002; 
Figures 3A,B), regardless of opsonization (Figure 3C). SIRT2−/− 
BMDMs also exhibited higher phagocytosis using a panel of 
fluorescently labeled heat-inactivated bacteria (% of SIRT2−/− vs 
SIRT2+/+ BMDMs ingesting bacteria: E. coli J5: 53.6 vs 43.6%, E. 
coli O111: 31.6 vs 23.0%, Salmonella Typhimurium: 24.1 vs 17.6%, 
Neisseria meningitis: 46.1 vs 37.2%, S. pneumoniae: 49.6 vs 34.7%). 
BMDMs were additionally exposed to live E. coli, S. aureus and 
GBS for 1 h before measuring the number of intracellular bacteria 
by plating cell lysates and enumerating colonies. Confirming the 
results obtained using inert beads and fluorescent bacteria, the 
numbers of phagocytosed E. coli, S. aureus and GBS were 1.3-fold 
to 1.6-fold higher using SIRT2−/− BMDMs (Figure 3D).
Macrophages express phagocytic receptors, including mac-
rophage scavenger receptor 1 (Msr1/SR-AI/CD204), CD14, 
CD36, C-type lectins such as dectin-1 (encoded by Clec7a), and 
members of the integrin superfamily (integrin α5/Itga5/CD49e, 
integrin αM/Itgam/CD11b, integrin αX/Itgax/CD11c, integrin 
β2/Itgb2/CD18). SIRT2−/− and SIRT2+/+ BMDMs expressed 
comparable mRNA levels of Itga5, Itga6, Itgal, Itgam, Itgax, Itgb1, 
Itgb2, Cd14, Cd36, Msr1, and Clec7a (Figure  3E). Moreover, 
SIRT2−/− and SIRT2+/+ BMDMs expressed similar levels of 
membrane-bound CD11b, CD11c, CD14, and Msr1 (Figure 3F). 
Hence, SIRT2 deficiency likely improved phagocytosis by 
BMDMs in a phagocytic receptor independent fashion.
Stabilization of microtubules and high glycolytic activity have 
been associated with efficient phagocytosis by macrophages 
(37–40). Since SIRT2 impacts on microtubules stabilization and 
glucose metabolism (8, 13, 41), we questioned whether these 
processes influenced phagocytosis by SIRT2−/− BMDMs. In 
FigUre 2 | Sirtuin 2 (SIRT2) deficiency does not affect proliferation and cytokine response of splenocytes and IFNγ production in mice challenged with toxic shock 
syndrome toxin-1 (TSST-1). (a,B) SIRT2+/+ and SIRT2−/− splenocytes were incubated for 48 h with lipopolysaccharide (LPS) (5 µg/ml), CpG (2 µg/ml), concanavalin 
A (5 µg/ml), anti-CD3/CD28 antibodies (1 µg/ml), phytohemagglutinin (PHA) (10 µg/ml), TSST-1 (2 µg/ml), and staphylococcal enterotoxin B (SEB) (5 µg/ml). 
Proliferation was measured by 3H-thymidine incorporation (a) while IL-2 and IFNγ concentrations in cell culture supernatants were quantified by ELISA  
(B). Data are means ± SD of triplicate samples from one experiment performed with four mice and are representative of two experiments (*P < 0.05).  
(c) SIRT2+/+ and SIRT2−/− mice (n = 8 per group) were injected with TSST-1 (0.5 mg/kg i.p.). Blood was collected after 0, 8, and 24 h to quantify IFNγ 
concentrations. Data are means ± SD. P > 0.5 for all time points. (D) SIRT2+/+ and SIRT2−/− splenocytes were incubated for 48 h with LPS, CpG, concanavalin A, 
anti-CD3/CD28 antibodies, PHA, TSST-1, and SEB. TNF, IL-6, IL-10, IL-12p70, CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES) were quantified by Luminex. 
Data (in pg/ml) are means ± SD of one experiment performed with three mice. CCL3 values in response to anti-CD3/CD8 were over the upper limit of detection of 
the assay (*P < 0.05).
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BMDMs, SIRT2 deficiency increased 1.5-fold tubulin acetylation 
(Figure 3G), a hallmark of microtubule stabilization. However, 
the microtubule destabilizer nocodazole did not impair the 
phagocytosis of S. aureus by BMDMs (Figure  3H), while the 
actin depolymerization agent cytochalasin D efficiently inhibited 
phagocytosis. Interestingly, the glycolytic activity was higher in 
SIRT2−/− than SIRT2+/+ BMDMs exposed to S. aureus (Figure 3I). 
Moreover, 2-DG, which inhibits glycolysis, significantly reduced 
the phagocytosis of S. aureus by BMDMs (Figure  3J). Albeit 
preliminary, these results suggested that differences in the meta-
bolic capacity of SIRT2+/+ and SIRT2−/− BMDMs may provide a 
mechanism by which SIRT2 impedes phagocytosis.
sirT2 Deficiency Does not affect 
cytokine response of BMDMs exposed  
to Microbial ligands and sensitivity of 
Mice to endotoxemia
Sensing of microbial ligands through TLRs initiates MAPK and 
NF-κB signaling involved in the control of cytokine gene expression 
by innate immune cells (2). To address whether SIRT2 impacted 
intracellular signaling, the phosphorylation of ERK1/2, p38, and 
JNK MAPKs in BMDMs exposed to LPS for 0, 10, 30, and 60 min 
was analyzed by western blotting. The rate of LPS-induced phos-
phorylation of ERK1/2, p38 and JNK was very similar in SIRT2+/+ 
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FigUre 3 | Continued
and SIRT2−/− BMDMs, with only a slight and late reduction of 
ERK1/2 phosphorylation in SIRT2−/− BMDMs (30% reduction at 
1 hour) (Figure 4A). The nuclear translocation of phosphorylated 
NF-κB p65 was not different in SIRT2+/+ and SIRT2−/− BMDMs 
exposed to LPS for 0, 10, 30, and 60 min (P > 0.5 for all time points).
SIRT2+/+ and SIRT2−/− BMDMs exposed to LPS, Pam3CSK4, 
CpG (i.e., TLR4, TLR1/2 and TLR9 ligands, respectively), and 
E. coli upregulated Tnf and Il6 mRNA levels and secreted TNF 
and IL-6 to the same extend (Figure  4B). Additionally, Tlr1, 
Tlr2, Tlr4, and Tlr9 mRNA were modulated likewise in SIRT2+/+ 
FigUre 3 | Continued  
Sirtuin 2 (SIRT2) deficiency increases bacterial phagocytosis by macrophages. (a–c) SIRT2+/+ and SIRT2−/− BM-derived macrophages (BMDMs) were incubated 
with 10 fluorescent beads [opsonized in (c)] per cell. After 1 h, cells were analyzed by flow cytometry. Representative histograms are depicted in (a,c).  
The percentage of fluorescent cells was calculated (B). Data are means ± SD from an experiment performed with four mice (*P = 0.002). (D) SIRT2+/+ and 
SIRT2−/− BMDMs were incubated with live Escherchia coli, Staphylococcus aureus, and Group B Streptococcus (GBS) (10 bacteria/cell). Phagocytosis was 
assessed after 1 h. Data are means ± SD from one experiment performed with four (E. coli and GBS) or eight (S. aureus) mice. *P = 0.03, 0.006, and 0.03 for 
E. coli, S. aureus, and GBS, respectively. (e) Itga5, Itga6, Itgal, Itgam, Itgax, Itgb1, Itgb2, Cd14, Cd36, Msr1, and Clec7a mRNA expression levels in SIRT2+/+ and 
SIRT2−/− BMDMs. Data are means ± SD of one experiment performed with three mice. (F) CD11b, CD11c, CD14, and Msr1 expression levels were analyzed by 
flow cytometry. The gray histogram represents staining with an isotype control antibody. (g) Expression levels of acetylated (Ac) and total tubulin in BMDMs were 
analyzed by western blotting and quantified by imaging. Data are means ± SD from six mice (right panel) (*P = 0.015). Full-length blots are presented in Figure S2 in 
Supplementary Material. (h) Phagocytosis of S. aureus [performed as in (D)] by SIRT2−/− BMDMs preincubated for 1 h with or without nocodazole (10 µM) and 
cytochalasin D (10 µM). Data are means ± SD from one experiment performed with four mice (*P = 0.008). (i) Glycolytic capacity of BMDMs assessed by measuring 
the extracellular acidification rate (ECAR) using the Seahorse XF Glycolysis Stress Test Kit as described in Section “Materials and Methods.” Data are means ± SD 
from one experiment performed with three mice. (J) Phagocytosis of S. aureus [performed as in (D)] by SIRT2−/− BMDMs preincubated for 1 h with or without 
25 mM 2-deoxy-glucose (2-DG). Data are means ± SD from one experiment performed with four mice (*P = 0.017).
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and SIRT2−/− BMDMs (Figure S3 in Supplementary Material). 
SIRT2+/+ and SIRT2−/− BMDMs expressed also comparable 
mRNA levels of Il1a, Il1b, Il10, Il12b, Il15, Il18, Il27, Ccl2/Mcp1, 
Ccl3/Mip1a, Ccl4/Mip1b, Ccl5/Rantes, Ccl8/Mcp2, Ccl12/
Mcp5, Cxcl10/Ip10, and Cxcl11/Itac at baseline and following 
LPS stimulation (Figure  4C), and secreted comparable levels 
of IL-10, IL-12p70, IL-18, CXCL10, CCL2, CCL3, CCL4, and 
CCL5 upon exposure to LPS, Pam3CSK4, CpG, E. coli, and S. 
aureus (Figure 4D). Altogether, these results argued against an 
important role of SIRT2 in controlling proinflammatory and 
anti-inflammatory cytokine response by macrophages exposed 
to TLR ligands.
To assess the relevance of these observations in  vivo, 
we developed models of endotoxemia of different severity 
(Figures 5A–D). In a mild model of endotoxemia (induced by 
an i.p. challenge with 10 mg/kg LPS), TNF and IL-12p40 con-
centrations in blood and mortality rates (83 vs 100%, P = 0.3) 
were comparable in SIRT2+/+ and SIRT2−/− mice (Figures 5A,B). 
In a severe model of endotoxemia (induced by 25 mg/kg LPS), 
TNF, IL-6, and IL-12p40 concentrations in blood and mortality 
rates (88% in both groups, P = 0.69) were strongly increased, but 
remained similar in SIRT2+/+ and SIRT2−/− mice (Figures 5C,D). 
Furthermore, SIRT2+/+ and SIRT2−/− mice were equally sensi-
tive to fulminant shock induced by TNF (25  mg/kg i.p. in 
d-galactosamine sensitized mice), the main driver of the lethal 
effect of endotoxemia (P = 0.6; Figure 5E). Overall, SIRT2 did 
not interfere with endotoxemia.
sirT2 Deficiency Protects from  
chronic staphylococcal infection
Considering that SIRT2 impacted phagocytosis but not cytokine 
expression, we hypothesized that SIRT2 deficiency should provide 
some benefit during chronic lethal infection but not fulminant 
sepsis, and should not sensitize to benign infection. Therefore, we 
compared the impact of SIRT2 deficiency during rapidly lethal, 
sub-lethal, and chronic bacterial infections induced by E. coli, K. 
pneumonia, and S. aureus, three of the most frequent causes of 
bacterial sepsis in humans (42).
Supporting our working hypothesis, in a model of chronic 
infection by S. aureus in which mortality occurred 3 to 16 days 
post i.v. challenge with the bacteria, severity score, body weight 
loss, and survival (SIRT2+/+ vs SIRT2−/−: 33.3 vs 69.2%; P = 0.04) 
were all markedly improved in SIRT2−/− mice (Figure  6A). In 
agreement with these findings, 48  h postinfection, only 37.5% 
(3/8) of SIRT2−/− mice were bacteremic while 71.4% (5/7) of 
SIRT2+/+ mice were bacteremic (Figure 6B). Moreover, bacterial 
burden in the spleen was much lower in SIRT2−/− than in SIRT2+/+ 
mice (1.9 × 102 vs 3.3 × 103 mean CFU/organ; P = 0.04). TNF 
was not detected in blood, while IL-6 and IL-12p40 levels were 
not different between SIRT2−/− and SIRT2+/+ mice, although 
there was a trend toward lower IL-12p40 levels in SIRT2−/− mice 
(Figure 6C). In a model of fulminant, rapidly lethal peritonitis 
induced by E. coli, body weight loss, bacterial dissemination 
into the blood, and survival rate (12.5% in both groups, P = 0.7) 
were comparable in SIRT2+/+ and SIRT2−/− mice (Figure 6D). In 
a non-severe model of K. pneumoniae pneumonia, body weight 
loss and survival (85.7% in both groups, P  =  0.9) were not 
affected by SIRT2 deficiency (Figure 6E). Finally, we questioned 
whether SIRT2 influenced host susceptibility to a non-bacterial 
chronic infection. Candidiasis was induced by i.v. inoculation of 
105 CFU/ml C. albicans into SIRT2+/+ and SIRT2−/− mice (n = 14 
and 16). Mice died 9–40 days postinfection, without survival dif-
ferences between the SIRT2+/+ and SIRT2−/− groups (71 vs 56%; 
P = 0.4), suggesting that SIRT2 deficiency did not compromise 
host defenses to Candida infection.
DiscUssiOn
In the present study, we identified a unique role for SIRT2 in 
host–pathogen interactions. SIRT2 deficiency promoted bacterial 
phagocytosis by macrophages but not cytokine production. In 
agreement with these findings, SIRT2 deficiency protected from 
chronic staphylococcal infection while having no influence on 
the course of endotoxemia, TNF-induced shock, fulminant bac-
terial peritonitis, non-severe bacterial pneumonia, and chronic 
candidiasis. These observations are particularly relevant in light 
of the development of pharmacological inhibitors of SIRT2 for 
clinical applications (43), as they suggest that their usage would 
not increase susceptibility to bacterial and candidal infections.
SIRT2 was the most highly expressed sirtuin in myeloid cells. 
Macrophages expressed elevated levels of SIRT2, in accordance 
previous reports describing SIRT2 expression in microglial cells 
in vivo (16, 17). Interestingly, SIRT2 deficiency had no major impact 
on LPS-induced MAPK activation, NF-κB nuclear translocation, 
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FigUre 4 | Continued
FigUre 5 | Sirtuin 2 (SIRT2) deficiency does not affect endotoxemia and TNF-induced shock. SIRT2+/+ and SIRT2−/− mice were injected i.p. with 10 mg/kg 
lipopolysaccharide (LPS) [(a,B), n = 6 per group] and 25 mg/kg LPS (c,D, n = 8 per group). (a,c) TNF, IL-6, and IL-12p40 concentrations in blood collected 1 h 
(TNF) and 6 h (IL-6 and IL-12p40) after LPS challenge. P > 0.5 for all conditions. (B,D) Survival of mice. P = 0.3 and 0.9. (e) Survival of SIRT2+/+ and SIRT2−/− mice 
(n = 11 per group) sensitized with 30 mg/kg d-galactosamine and challenged i.p. with 25 mg/kg TNF. P = 0.6.
FigUre 4 | Contiued  
Sirtuin 2 (SIRT2) deficiency does not affect the response of macrophages to microbial stimulation. SIRT2+/+ and SIRT2−/− BM-derived macrophages were exposed to 
lipopolysaccharide (LPS) (10 ng/ml), Pam3CSK4 (10 ng/ml), CpG (2 µg/ml), Escherichia coli (106 CFU/ml), and Staphylococcus aureus (106 CFU/ml). (a) Expression 
levels of phosphorylated (p) and total ERK1/2 (upper panel), p38 and JNK were analyzed by western blotting and quantified by imaging. Data are means ± SD from 
one experiment performed with three mice (lower panel) (*P = 0.02). (B) Tnf and Il6 mRNA levels and TNF and IL-6 concentrations in cell culture supernatants 1 and 
8 h after stimulation, respectively. (c) Il1a, Il1b, Il10, Il12b, Il15, Il18, Il27, Ccl2/Mcp1, Ccl3/Mip1a, Ccl4/Mip1b, Ccl5/Rantes, Ccl8/Mcp2, Ccl12/Mcp5, Cxcl10/Ip10, 
Cxcl11/Itac mRNA levels after 8 h of culture with or without LPS. (D) IL-10, IL-12p70, IL-18, CXCL10, CCL2, CCL3, CCL4, and CCL5 concentrations in cell culture 
supernatants 8 h after stimulation measured by Luminex. Data are means ± SD of triplicate samples from one experiment performed with three mice (mRNA 
analyses) or six mice (TNF and IL-6 secretion), or means ± SD of single measurements from one experiment performed with three mice (Luminex). CXCL10 values in 
response to E. coli were over the upper limit of detection of the assay. No statistically significant differences were detected in (B–D). A.U., arbitrary units. Full-length 
blots of panel (a) are presented in Figure S4 in Supplementary Material.
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and cytokine production in macrophages. Moreover, cytokine 
levels in blood were similar in SIRT2+/+ and SIRT2−/− endotox-
emic mice. Likewise, inflammatory parameters were comparable 
in SIRT2+/+ and SIRT2−/− mice with experimental stroke and 
Mycobacterium tuberculosis infection (21, 44). However, contra-
dictory findings have been reported in the literature. While SIRT2 
deficiency promoted NF-κB p65 acetylation and p65-dependent 
gene expression, it was also reported to reduce NF-κB and p38 
and JNK MAPKs activation through an increased stability of IκB 
and activity of MAPK phosphatase-1, respectively (14–16, 18, 20, 
45). In these studies, SIRT2 deficiency sustained brain inflamma-
tion, colitis, and collagen-induced arthritis, but protected from 
renal and liver inflammation (15, 16, 18, 20, 45).
The discrepancy of the effects of SIRT2 on inflammatory 
responses mirrors conflicting results observed for other sirtuins. 
For example, SIRT1 protected from experimental autoimmune 
FigUre 6 | SIRT2 deficiency protects from chronic Staphytococcus aureus infection. (a) Severity score (*P ≤ 0.01), body weight (*P = 0.03 and 0.04) and survival 
(P = 0.04) of SIRT2+/+ and SIRT2−/− mice challenged i.v. with 107 CFU S. aureus (n = 13 and 9). (B,c) Blood and spleen were collected from SIRT2+/+ and 
SIRT2−/− mice (n = 7 and 8) 48 h after S. aureus challenge. Bacteria were quantified in blood and spleen (B) while IL-6 and IL-12p40 concentrations were quantified 
in blood (c). Horizontal bars represent the medians. P = 0.07 and 0.04 in (B), and P = 0.95 and 0.12 in (c). (D) Body weight, bacteria in blood 18 h postinfection 
(P = 0.9), and survival (P = 0.8) of SIRT2+/+ and SIRT2−/− mice challenged i.p. with 105 CFU E. coli (n = 16 per group). (e) Body weight and survival (P = 0.9) of 
SIRT2+/+ and SIRT2−/− mice challenged i.n. with 30 CFU K. pneumoniae (n = 7 per group).
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encephalomyelitis, arthritis, lung inflammation, hepatic steatosis, 
and insulin resistance, but promoted lupus, arthritis, allergic air-
way disease, and allograft rejection (46–54). SIRT6 has not only 
been reported to protect against liver fibrosis, atherosclerosis, 
osteoarthritis, and arthritis but has also been associated with 
increased TNF production and the development of autoimmune 
encephalomyelitis and cerebral ischemia (55–62). Different 
experimental conditions might explain these apparent conflict-
ing results, for example qualitative and quantitative differences 
in caloric input or subtle variations of NAD+ availability influ-
encing sirtuin activity indirectly. Moreover, SIRT1, SIRT3, and 
SIRT6 modulate circadian function and are affected by circadian 
12
Ciarlo et al. Impact of SIRT2 on Innate Immune Responses
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1037
oscillation in the abundance of NAD+ (63, 64). Furthermore, 
sirtuins might primarily play a role in the development of 
long-lasting, chronic metabolic, and/or inflammation-related 
disorders while having a modest impact during acute infectious 
processes. For instance, SIRT3 deficiency has been reported to 
increase insulin resistance, diabetic cardiac dysfunction, allo-
graft graft injury, and lung fibrosis, but had no impact on innate 
immune responses and susceptibility to endotoxemia or bacterial 
and fungal sepsis (65–73).
Two prior studies examined SIRT2 in the context of infection 
by intracellular bacteria. SIRT2 deletion in the myeloid compart-
ment had no noticeable impact on host defenses against M. 
tuberculosis infection as attested by cellular infiltrates, cytokine 
expression, and long-term bacterial burden in lungs (44). Listeria 
monocytogenes promoted SIRT2-dependent histone H3 deacety-
lation and redirected host gene expression to favor infection (74). 
Whether other microorganisms subvert SIRT2 or other sirtuins at 
their own benefit is unknown.
We analyzed host responses to extracellular bacteria most 
frequently isolated from septic patients. Strikingly, SIRT2 
deficiency enhanced the engulfment of Gram-positive and 
Gram-negative bacteria by macrophages, an effect apparently 
unrelated with a differential expression of phagocytic receptors 
or microtubule polymerization. This observation was surprising 
considering that on the one hand SIRT2 deacetylates α-tubulin 
and destabilizes the microtubule network (8, 41) and on the 
other end microtubule depolymerizating agents were reported 
to inhibit phagocytosis (75, 76). Yet, the effects of microtubule 
depolymerizating agents were tested using an immortalized 
macrophage-like mouse cell line and human neutrophils that 
may behave differently than primary BMDMs. As a positive 
control (77), actin depolymerization efficiently inhibited phago-
cytosis by BMDMs. Increased glycolysis has been associated with 
efficient phagocytosis by macrophages (39, 40). SIRT2 deficiency 
reduced HIF-1α deacetylation and destablization (78), and aug-
mented glycolysis in human fibroblasts (79). We observed that 
SIRT2 deficiency increased glycolysis and that glycolysis inhibi-
tion reduced phagocytosis in BMBMs. Albeit preliminary, these 
results suggest that SIRT2 may influence phagocytosis through 
metabolic constraints.
The improved control of bacterial burden during chronic 
staphylococcal infection might be related to improved phagocy-
tosis but also to enhanced autophagy in SIRT2−/− mice. Autophagy 
facilitates the clearance of cytoplasmic bacteria (80) and has been 
involved in host defenses and tolerance to S. aureus infection (81, 
82). Hyperacetylation of tubulin stimulated autophagy upon 
nutrient deprivation, and SIRT2 deficiency increased autophagy 
in a colorectal cancer cell line (83, 84). Thus, by regulating 
tubulin acetylation and metabolic activity, SIRT2 may contribute 
to modulate phagocytic and autophagy defense mechanisms, 
though the latter has not been formally demonstrated.
From a translational perspective, it was important to define 
the impact of SIRT2 in preclinical models of infection. A main 
observation of this study is that SIRT2 deficiency protected mice 
from chronic staphylococcal infection, while it neither protected 
nor sensitized mice to TNF-induced shock, endotoxemia, rapidly 
lethal E. coli peritonitis and mild K. pneumoniae pneumonia. 
Additionally, SIRT2 deficiency did not influence the develop-
ment of chronic candidiasis as it did for chronic staphylococcal 
infection. This may not be surprising considering differences in 
host–pathogen interactions during fungal and bacterial infec-
tions. Whether SIRT2 protects from other chronic bacterial 
infections should be tested in the future. Nonetheless, these 
results support the clinical development of SIRT2 inhibitors 
regarding their infection-related safety profile. This contrasts 
with inhibitors of HDAC1-11 that impaired innate immune 
defenses, increased susceptibility to infection in preclinical 
mouse models and have been associated with severe infections 
in patients (29, 85–89).
Overall, SIRT2 has a subtle impact on host defense responses 
to bacterial infections. Considering that sirtuins are intricately 
linked with metabolism, age-associated dysfunctions and lifes-
pan, it will be important to analyze the impact of SIRT2 on host 
defenses under metabolic stress conditions and according to age. 
To conclude, our results are encouraging with respect to develop-
ing inhibitors of SIRT2, which are safe in terms of susceptibility to 
infections, for treating metabolic and neurodegenerative diseases, 
such as Parkinson’s disease and Huntington’s disease (90, 91).
eThics sTaTeMenT
Animal experimentation was approved by the Service de la 
Consommation et des Affaires Vétérinaires (SCAV) du Canton de 
Vaud (Epalinges, Switzerland) under authorizations no. 876.8 and 
877.8, and performed according to Swiss and ARRIVE guidelines.
aUThOr cOnTriBUTiOns
EC, TH, CT, JH, MM, JL, MP, BT, and SL performed in  vitro 
experiments. EC, TH, CT, and DLR performed in  vivo experi-
ments. HA-O and JA contributed to reagents. TR conceived the 
project, designed the experiments, and wrote the paper. All the 
authors revised the paper.
FUnDing
This work was supported by grants from the Swiss National 
Science Foundation (SNSF) 145014, 149511, 173123 (TR), 
132492 (HA-O), and 140780 (JA). TR received an interdisci-
plinary grant from the Faculty of Biology and Medicine of the 
University of Lausanne (Switzerland). CT was supported by the 
European Sepsis Academy Horizon 2020 Marie Skłodowska-
Curie Action: Innovative Training Network (MSCA-ESA-ITN, 
grant number 676129). BT and SL were supported by the Summer 
Undergraduate Research (SUR) program of the University of 
Lausanne. The work in the JA laboratory was supported by the 
EPFL, NIH (R01AG043930), Systems X (SySX.ch 2013/153), and 
Velux Stiftung (1019).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.01037/full#supplementary-material.
13
Ciarlo et al. Impact of SIRT2 on Innate Immune Responses
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1037
reFerences
1. Broz P, Monack DM. Newly described pattern recognition receptors team 
up against intracellular pathogens. Nat Rev Immunol (2013) 13:551–65. 
doi:10.1038/nri3479 
2. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic 
strategies for the management of sepsis-associated pathology and infectious 
diseases. Front Immunol (2013) 4:387. doi:10.3389/fimmu.2013.00387 
3. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in 
cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 
(2014) 13:673–91. doi:10.1038/nrd4360 
4. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and 
disease relevance. Annu Rev Pathol (2010) 5:253–95. doi:10.1146/annurev.
pathol.4.110807.092250 
5. Guarente L. Franklin H. Epstein Lecture: sirtuins, aging, and medicine. N Engl 
J Med (2011) 364:2235–44. doi:10.1056/NEJMra1100831 
6. Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science 
(2015) 350:1208–13. doi:10.1126/science.aac4854 
7. Preyat N, Leo O. Sirtuin deacylases: a molecular link between metabolism and 
immunity. J Leukoc Biol (2013) 93:669–80. doi:10.1189/jlb.1112557 
8. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 
ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell (2003) 
11:437–44. doi:10.1016/S1097-2765(03)00038-8 
9. Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases 
of aging. Cell Res (2013) 23:746–58. doi:10.1038/cr.2013.70 
10. Teng YB, Jing H, Aramsangtienchai P, He B, Khan S, Hu J, et  al. Efficient 
demyristoylase activity of SIRT2 revealed by kinetic and structural studies. 
Sci Rep (2015) 5:8529. doi:10.1038/srep08529 
11. Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegener-
ation. EMBO Mol Med (2013) 5:344–52. doi:10.1002/emmm.201302451 
12. Kozako T, Suzuki T, Yoshimitsu M, Arima N, Honda S, Soeda S. Anticancer 
agents targeted to sirtuins. Molecules (2014) 19:20295–313. doi:10.3390/
molecules191220295 
13. Gomes P, Outeiro TF, Cavadas C. Emerging role of sirtuin 2 in the regula-
tion of mammalian metabolism. Trends Pharmacol Sci (2015) 36:756–68. 
doi:10.1016/j.tips.2015.08.001 
14. Rothgiesser KM, Erener S, Waibel S, Luscher B, Hottiger MO. SIRT2 regulates 
NF-kappaB dependent gene expression through deacetylation of p65 Lys310. 
J Cell Sci (2010) 123:4251–8. doi:10.1242/jcs.073783 
15. Lo Sasso G, Menzies KJ, Mottis A, Piersigilli A, Perino A, Yamamoto H, et al. 
SIRT2 deficiency modulates macrophage polarization and susceptibility 
to experimental colitis. PLoS One (2014) 9:e103573. doi:10.1371/journal.
pone.0103573 
16. Pais TF, Szego EM, Marques O, Miller-Fleming L, Antas P, Guerreiro P, 
et al. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial 
activation and brain inflammation. EMBO J (2013) 32:2603–16. doi:10.1038/
emboj.2013.200 
17. Yuan F, Xu ZM, Lu LY, Nie H, Ding J, Ying WH, et  al. SIRT2 inhibition 
exacerbates neuroinflammation and blood-brain barrier disruption in exper-
imental traumatic brain injury by enhancing NF-kappaB p65 acetylation and 
activation. J Neurochem (2016) 136:581–93. doi:10.1111/jnc.13423 
18. Jung YJ, Lee AS, Nguyen-Thanh T, Kim D, Kang KP, Lee S, et  al. SIRT2 
regulates LPS-induced renal tubular CXCL2 and CCL2 expression. J Am Soc 
Nephrol (2015) 26:1549–60. doi:10.1681/ASN.2014030226 
19. Lee AS, Jung YJ, Kim D, Nguyen-Thanh T, Kang KP, Lee S, et al. SIRT2 ame-
liorates lipopolysaccharide-induced inflammation in macrophages. Biochem 
Biophys Res Commun (2014) 450:1363–9. doi:10.1016/j.bbrc.2014.06.135 
20. Wang J, Koh HW, Zhou L, Bae UJ, Lee HS, Bang IH, et al. Sirtuin 2 aggravates 
postischemic liver injury by deacetylating mitogen-activated protein kinase 
phosphatase-1. Hepatology (2017) 65:225–36. doi:10.1002/hep.28777 
21. Krey L, Luhder F, Kusch K, Czech-Zechmeister B, Konnecke B, Outeiro TF, 
et  al. Knockout of silent information regulator 2 (SIRT2) preserves neuro-
logical function after experimental stroke in mice. J Cereb Blood Flow Metab 
(2015) 35:2080–8. doi:10.1038/jcbfm.2015.178 
22. Ciarlo E, Heinonen T, Herderschee J, Fenwick C, Mombelli M, Le Roy D, 
et  al. Impact of the microbial derived short chain fatty acid propionate on 
host susceptibility to bacterial and fungal infections in vivo. Sci Rep (2016) 
6:37944. doi:10.1038/srep37944 
23. Renner P, Roger T, Bochud PY, Sprong T, Sweep FC, Bochud M, et  al.  
A functional microsatellite of the macrophage migration inhibitory factor 
gene associated with meningococcal disease. FASEB J (2012) 26:907–16. 
doi:10.1096/fj.11-195065 
24. Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, Mauri D, 
et al. Protection from lethal Gram-negative bacterial sepsis by targeting toll-
like receptor 4. Proc Natl Acad Sci U S A (2009) 106:2348–52. doi:10.1073/
pnas.0808146106 
25. Roger T, Schneider A, Weier M, Sweep FC, Le Roy D, Bernhagen J, et  al. 
High expression levels of macrophage migration inhibitory factor sustain 
the innate immune responses of neonates. Proc Natl Acad Sci U S A (2016) 
113:E997–1005. doi:10.1073/pnas.1514018113 
26. Savva A, Brouwer MC, Roger T, Valls Seron M, Le Roy D, Ferwerda B, et al. 
Functional polymorphisms of macrophage migration inhibitory factor as 
predictors of morbidity and mortality of pneumococcal meningitis. Proc Natl 
Acad Sci U S A (2016) 113:3597–602. doi:10.1073/pnas.1520727113 
27. Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, 
et  al. T(H)17 cells promote microbial killing and innate immune sensing 
of DNA via interleukin 26. Nat Immunol (2015) 16:970–9. doi:10.1038/ 
ni.3211 
28. Ciarlo E, Roger T. Screening the impact of sirtuin inhibitors on inflammatory 
and innate immune responses of macrophages and in a mouse model of 
endotoxic shock. Methods Mol Biol (2016) 1436:313–34. doi:10.1007/978-1- 
4939-3667-0_21 
29. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, et  al. 
Histone deacetylase inhibitors impair innate immune responses to toll-like 
receptor agonists and to infection. Blood (2011) 117:1205–17. doi:10.1182/
blood-2010-05-284711 
30. Roger T, Ding X, Chanson AL, Renner P, Calandra T. Regulation of constitutive 
and microbial pathogen-induced human macrophage migration inhibitory 
factor (MIF) gene expression. Eur J Immunol (2007) 37:3509–21. doi:10.1002/
eji.200737357 
31. Roger T, Out TA, Jansen HM, Lutter R. Superinduction of interleukin-6 
mRNA in lung epithelial H292 cells depends on transiently increased C/EBP 
activity and durable increased mRNA stability. Biochim Biophys Acta (1998) 
1398:275–84. doi:10.1016/S0167-4781(98)00075-X 
32. Giannoni E, Guignard L, Knaup Reymond M, Perreau M, Roth-Kleiner M, 
Calandra T, et  al. Estradiol and progesterone strongly inhibit the innate 
immune response of mononuclear cells in newborns. Infect Immun (2011) 
79:2690–8. doi:10.1128/IAI.00076-11 
33. Perreau M, Vigano S, Bellanger F, Pellaton C, Buss G, Comte D, et  al. 
Exhaustion of bacteria-specific CD4 T  cells and microbial translocation in 
common variable immunodeficiency disorders. J Exp Med (2014) 211:2033–45. 
doi:10.1084/jem.20140039 
34. Lugrin J, Ciarlo E, Santos A, Grandmaison G, dos Santos I, Le Roy D, et al. 
The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflamma-
tory and innate immune responses and protects from septic shock. Biochim 
Biophys Acta (2013) 1833:1498–510. doi:10.1016/j.bbamcr.2013.03.004 
35. Vacher G, Ciarlo E, Savova-Bianchi D, Le Roy D, Hantier G, Niculita-Hirzel H, 
et al. Innate immune sensing of Fusarium culmorum by mouse dendritic cells. 
J Toxicol Environ Health A (2015) 78:871–85. doi:10.1080/15287394.2015.10
51201 
36. Roger T, Delaloye J, Chanson AL, Giddey M, Le Roy D, Calandra T. 
Macrophage migration inhibitory factor deficiency is associated with impaired 
killing of Gram-negative bacteria by macrophages and increased susceptibility 
to Klebsiella pneumoniae sepsis. J Infect Dis (2013) 207:331–9. doi:10.1093/
infdis/jis673 
37. Niedergang F, Di Bartolo V, Alcover A. Comparative anatomy of phagocytic 
and immunological synapses. Front Immunol (2016) 7:18. doi:10.3389/
fimmu.2016.00018 
38. Westermann S, Weber K. Post-translational modifications regulate microtu-
bule function. Nat Rev Mol Cell Biol (2003) 4:938–47. doi:10.1038/nrm1260 
39. Fensterheim BA, Guo Y, Sherwood ER, Bohannon JK. The cytokine response to 
lipopolysaccharide does not predict the host response to infection. J Immunol 
(2017) 198:3264–73. doi:10.4049/jimmunol.1602106 
40. Pavlou S, Wang L, Xu H, Chen M. Higher phagocytic activity of thioglycollate- 
elicited peritoneal macrophages is related to metabolic status of the cells. 
J Inflamm (Lond) (2017) 14:4. doi:10.1186/s12950-017-0151-x 
14
Ciarlo et al. Impact of SIRT2 on Innate Immune Responses
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1037
41. Yuan Q, Zhan L, Zhou QY, Zhang LL, Chen XM, Hu XM, et al. SIRT2 regulates 
microtubule stabilization in diabetic cardiomyopathy. Eur J Pharmacol (2015) 
764:554–61. doi:10.1016/j.ejphar.2015.07.045 
42. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet (2005) 365:63–78. 
doi:10.1016/S0140-6736(04)17667-8 
43. Villalba JM, Alcain FJ. Sirtuin activators and inhibitors. Biofactors (2012) 
38:349–59. doi:10.1002/biof.1032 
44. Cardoso F, Castro F, Moreira-Teixeira L, Sousa J, Torrado E, Silvestre R, et al. 
Myeloid sirtuin 2 expression does not impact long-term Mycobacterium 
tuberculosis control. PLoS One (2015) 10:e0131904. doi:10.1371/journal.
pone.0131904 
45. Lin J, Sun B, Jiang C, Hong H, Zheng Y. Sirt2 suppresses inflammatory 
responses in collagen-induced arthritis. Biochem Biophys Res Commun (2013) 
441:897–903. doi:10.1016/j.bbrc.2013.10.153 
46. Hah YS, Cheon YH, Lim HS, Cho HY, Park BH, Ka SO, et al. Myeloid deletion 
of SIRT1 aggravates serum transfer arthritis in mice via nuclear factor-kappaB 
activation. PLoS One (2014) 9:e87733. doi:10.1371/journal.pone.0087733 
47. Kim SR, Lee KS, Park SJ, Min KH, Choe YH, Moon H, et  al. Involvement 
of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic 
airway disease. J Allergy Clin Immunol (2010) 125:449–60.e14. doi:10.1016/j.
jaci.2009.08.009 
48. Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, Fessler MB, et  al. 
Myeloid deletion of SIRT1 induces inflammatory signaling in response 
to environmental stress. Mol Cell Biol (2010) 30:4712–21. doi:10.1128/
MCB.00657-10 
49. Zhang J, Lee SM, Shannon S, Gao B, Chen W, Chen A, et al. The type III histone 
deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin 
Invest (2009) 119:3048–58. doi:10.1172/JCI38902 
50. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 
protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci 
U S A (2008) 105:9793–8. doi:10.1073/pnas.0802917105 
51. Legutko A, Marichal T, Fievez L, Bedoret D, Mayer A, de Vries H, et al. Sirtuin 
1 promotes Th2 responses and airway allergy by repressing peroxisome prolif-
erator-activated receptor-gamma activity in dendritic cells. J Immunol (2011) 
187:4517–29. doi:10.4049/jimmunol.1101493 
52. Niederer F, Ospelt C, Brentano F, Hottiger MO, Gay RE, Gay S, et al. SIRT1 
overexpression in the rheumatoid arthritis synovium contributes to proin-
flammatory cytokine production and apoptosis resistance. Ann Rheum Dis 
(2011) 70:1866–73. doi:10.1136/ard.2010.148957 
53. Hu N, Long H, Zhao M, Yin H, Lu Q. Aberrant expression pattern of histone 
acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/
lpr mice. Scand J Rheumatol (2009) 38:464–71. doi:10.3109/0300974090 
2895750 
54. Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G, et al. Sirtuin-1 targeting 
promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. 
Mol Cell Biol (2011) 31:1022–9. doi:10.1128/MCB.01206-10 
55. Lee HS, Ka SO, Lee SM, Lee SI, Park JW, Park BH. Overexpression of sirtuin 
6 suppresses inflammatory responses and bone destruction in mice with 
collagen-induced arthritis. Arthritis Rheum (2013) 65:1776–85. doi:10.1002/
art.37963 
56. Xiao C, Wang RH, Lahusen TJ, Park O, Bertola A, Maruyama T, et  al. 
Progression of chronic liver inflammation and fibrosis driven by activation 
of c-JUN signaling in Sirt6 mutant mice. J Biol Chem (2012) 287:41903–13. 
doi:10.1074/jbc.M112.415182 
57. Ailixiding M, Aibibula Z, Iwata M, Piao J, Hara Y, Koga D, et al. Pivotal role 
of Sirt6 in the crosstalk among ageing, metabolic syndrome and osteoar-
thritis. Biochem Biophys Res Commun (2015) 466:319–26. doi:10.1016/j.
bbrc.2015.09.019 
58. Balestrieri ML, Rizzo MR, Barbieri M, Paolisso P, D’Onofrio N, Giovane A, 
et al. Sirtuin 6 expression and inflammatory activity in diabetic atheroscle-
rotic plaques: effects of incretin treatment. Diabetes (2015) 64:1395–406. 
doi:10.2337/db14-1149 
59. Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, et al. 
Catastrophic NAD+ depletion in activated T  lymphocytes through Nampt 
inhibition reduces demyelination and disability in EAE. PLoS One (2009) 
4:e7897. doi:10.1371/journal.pone.0007897 
60. Jiang H, Khan S, Wang Y, Charron G, He B, Sebastian C, et al. SIRT6 regulates 
TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine. Nature 
(2013) 496:110–3. doi:10.1038/nature12038 
61. Lee OH, Kim J, Kim JM, Lee H, Kim EH, Bae SK, et al. Decreased expression of 
sirtuin 6 is associated with release of high mobility group box-1 after cerebral 
ischemia. Biochem Biophys Res Commun (2013) 438:388–94. doi:10.1016/j.
bbrc.2013.07.085 
62. Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov A, et  al. 
Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a 
sirtuin-dependent manner. Nat Med (2009) 15:206–10. doi:10.1038/nm.1906 
63. Peek CB, Affinati AH, Ramsey KM, Kuo HY, Yu W, Sena LA, et al. Circadian 
clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science 
(2013) 342:1243417. doi:10.1126/science.1243417 
64. Masri S, Sassone-Corsi P. Sirtuins and the circadian clock: bridging chromatin 
and metabolism. Sci Signal (2014) 7:re6. doi:10.1126/scisignal.2005685 
65. Akamata K, Wei J, Bhattacharyya M, Cheresh P, Bonner MY, Arbiser JL, 
et al. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its phar-
macologic activation mitigates organ fibrosis. Oncotarget (2016) 7:69321–36. 
doi:10.18632/oncotarget.12504 
66. Beier UH, Angelin A, Akimova T, Wang L, Liu Y, Xiao H, et al. Essential role 
of mitochondrial energy metabolism in Foxp3(+) T-regulatory cell function 
and allograft survival. FASEB J (2015) 29:2315–26. doi:10.1096/fj.14-268409 
67. Bindu S, Pillai VB, Kanwal A, Samant S, Mutlu GM, Verdin E, et al. SIRT3 
blocks myofibroblast differentiation and pulmonary fibrosis by preventing 
mitochondrial DNA damage. Am J Physiol Lung Cell Mol Physiol (2017) 
312:L68–78. doi:10.1152/ajplung.00188.2016 
68. Gao J, Zheng Z, Gu Q, Chen X, Liu X, Xu X. Deacetylation of MnSOD by 
PARP-regulated SIRT3 protects retinal capillary endothelial cells from hyper-
glycemia-induced damage. Biochem Biophys Res Commun (2016) 472:425–31. 
doi:10.1016/j.bbrc.2015.12.037 
69. Lantier L, Williams AS, Williams IM, Yang KK, Bracy DP, Goelzer M, et al. 
SIRT3 is crucial for maintaining skeletal muscle insulin action and protects 
against severe insulin resistance in high-fat-fed mice. Diabetes (2015) 
64:3081–92. doi:10.2337/db14-1810 
70. Morigi M, Perico L, Rota C, Longaretti L, Conti S, Rottoli D, et  al. Sirtuin 
3-dependent mitochondrial dynamic improvements protect against acute 
kidney injury. J Clin Invest (2015) 125:715–26. doi:10.1172/JCI77632 
71. Sosulski ML, Gongora R, Feghali-Bostwick C, Lasky JA, Sanchez CG. Sirtuin 
3 deregulation promotes pulmonary fibrosis. J Gerontol A Biol Sci Med Sci 
(2017) 72:595–602. doi:10.1093/gerona/glw151 
72. Yu W, Gao B, Li N, Wang J, Qiu C, Zhang G, et al. Sirt3 deficiency exacerbates 
diabetic cardiac dysfunction: role of Foxo3A-Parkin-mediated mitophagy. 
Biochim Biophys Acta (2017) 1863:1973–83. doi:10.1016/j.bbadis.2016.10.021 
73. Ciarlo E, Heinonen T, Lugrin J, Acha-Orbea H, Le Roy D, Auwerx J, et  al. 
Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal 
infections. Sci Rep (2017) 7:3853. doi:10.1038/s41598-017-04263-x 
74. Eskandarian HA, Impens F, Nahori MA, Soubigou G, Coppee JY, Cossart P, 
et al. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial 
infection. Science (2013) 341:1238858. doi:10.1126/science.1238858 
75. Horwitz SB, Chia GH, Harracksingh C, Orlow S, Pifko-Hirst S, Schneck J, et al. 
Trifluoperazine inhibits phagocytosis in a macrophagelike cultured cell line. 
J Cell Biol (1981) 91:798–802. doi:10.1083/jcb.91.3.798 
76. Roberts RL, Nath J, Friedman MM, Gallin JI. Effects of taxol on human 
neutrophils. J Immunol (1982) 129:2134–41. 
77. Hartwig JH, Stossel TP. Interactions of actin, myosin, and an actin-binding 
protein of rabbit pulmonary macrophages. III. Effects of cytochalasin B. J Cell 
Biol (1976) 71:295–303. doi:10.1083/jcb.71.1.295 
78. Seo KS, Park JH, Heo JY, Jing K, Han J, Min KN, et al. SIRT2 regulates tumour 
hypoxia response by promoting HIF-1alpha hydroxylation. Oncogene (2015) 
34:1354–62. doi:10.1038/onc.2014.76 
79. Cha Y, Han MJ, Cha HJ, Zoldan J, Burkart A, Jung JH, et al. Metabolic control 
of primed human pluripotent stem cell fate and function by the miR-200c-
SIRT2 axis. Nat Cell Biol (2017) 19:445–56. doi:10.1038/ncb3517 
80. Huang J, Brumell JH. Bacteria-autophagy interplay: a battle for survival. 
Nat Rev Microbiol (2014) 12:101–14. doi:10.1038/nrmicro3160 
81. Maurer K, Reyes-Robles T, Alonzo  F III, Durbin J, Torres VJ, Cadwell K. 
Autophagy mediates tolerance to Staphylococcus aureus alpha-toxin. Cell Host 
Microbe (2015) 17:429–40. doi:10.1016/j.chom.2015.03.001 
82. Wu HM, Wang J, Zhang B, Fang L, Xu K, Liu RY. CpG-ODN promotes phago-
cytosis and autophagy through JNK/P38 signal pathway in Staphylococcus 
aureus-stimulated macrophage. Life Sci (2016) 161:51–9. doi:10.1016/j.
lfs.2016.07.016 
15
Ciarlo et al. Impact of SIRT2 on Innate Immune Responses
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1037
83. Geeraert C, Ratier A, Pfisterer SG, Perdiz D, Cantaloube I, Rouault A, et al. 
Starvation-induced hyperacetylation of tubulin is required for the stimulation 
of autophagy by nutrient deprivation. J Biol Chem (2010) 285:24184–94. 
doi:10.1074/jbc.M109.091553 
84. Inoue T, Nakayama Y, Li Y, Matsumori H, Takahashi H, Kojima H, et  al. 
SIRT2 knockdown increases basal autophagy and prevents postslippage death 
by abnormally prolonging the mitotic arrest that is induced by microtubule 
inhibitors. FEBS J (2014) 281:2623–37. doi:10.1111/febs.12810 
85. Li Y, Liu B, Zhao H, Sailhamer EA, Fukudome EY, Zhang X, et al. Protective 
effect of suberoylanilide hydroxamic acid against LPS-induced septic 
shock in rodents. Shock (2009) 32:517–23. doi:10.1097/SHK.0b013e318 
1a44c79 
86. Mombelli M, Lugrin J, Rubino I, Chanson AL, Giddey M, Calandra T, et al. 
Histone deacetylase inhibitors impair antibacterial defenses of macrophages. 
J Infect Dis (2011) 204:1367–74. doi:10.1093/infdis/jir553 
87. Zhang LT, Yao YM, Lu JQ, Yan XJ, Yu Y, Sheng ZY. Sodium butyrate pre-
vents lethality of severe sepsis in rats. Shock (2007) 27:672–7. doi:10.1097/
SHK.0b013e31802e3f4c 
88. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, et al. Phase 1 
and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults 
with refractory and relapsed acute leukemias. Blood (2007) 109:2781–90. 
doi:10.1182/blood-2006-05-021873 
89. Ciarlo E, Savva A, Roger T. Epigenetics in sepsis: targeting histone 
deacetylases. Int J Antimicrob Agents (2013) 42(Suppl):S8–12. doi:10.1016/j.
ijantimicag.2013.04.004 
90. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore 
AM, et  al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity 
in models of Parkinson’s disease. Science (2007) 317:516–9. doi:10.1126/
science.1143780 
91. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, et al. 
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. 
Proc Natl Acad Sci U S A (2010) 107:7927–32. doi:10.1073/pnas.1002924107 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Ciarlo, Heinonen, Théroude, Herderschee, Mombelli, Lugrin, 
Pfefferlé, Tyrrell, Lensch, Acha-Orbea, Le Roy, Auwerx and Roger. This is an open- 
access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
